Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

A Clinical Link Between Peroxisome Proliferator-Activated Receptor γ and the Renin–Angiotensin System

Curt D. Sigmund
Download PDF
https://doi.org/10.1161/ATVBAHA.112.301125
Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:676-678
Originally published March 13, 2013
Curt D. Sigmund
From the Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA (C.D.S.).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • familial partial lipodystrophy
  • hypertension
  • reninangiotensin system
  • PPARγ

A mechanistic link between peroxisome proliferator-activated receptor γ (PPARγ) and the renin–angiotensin system (RAS) has been previously proposed, but clinical evidence supporting the relationship is incomplete. In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Caron-Debarle et al show that 4 patients with familial partial lipodystrophy associated with early-onset severe hypertension carry mutations in PPARγ that impair its ability to act as a ligand-activated transcription factor. Cells isolated from these patients, and cells transfected with the same mutations in PPARγ, exhibit activation of the cellular RAS, increased production of reactive oxygen species (ROS), and markers of inflammation, all of which are dependent on the angiotensin-II (Ang-II) AT1 receptor (AT1R). This translational study further supports a role for PPARγ as a regulator of blood pressure through its ability to modulate the RAS.

See accompanying article on page 829

PPARγ is a ligand-activated transcription factor and target of the thiazolidinedione (TZD) class of antidiabetes mellitus medications. PPARγ is best recognized for its role in adipogenesis, but is also a regulator of systemic metabolism as evidenced by the pleiotropic abnormalities (lipodystrophy, insulin-resistance, and metabolic syndrome) caused by PPARγ mutations.1–3 Clinical studies of TZD use in type 2 diabetes mellitus, including the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) trial, documented improved endothelial function and modest, but significant reductions in blood pressure.4 Some of the same mutations that cause lipodystrophy and diabetes mellitus also cause severe hypertension and preeclampsia in human patients3 and in knock-in mice.5,6 Evidence suggests that PPARγ activity in the vascular endothelium and smooth muscle are important regulators of endothelial function, smooth muscle contraction, and systemic blood pressure.7,8

Data suggesting a role for PPARγ in regulating blood pressure led many to search for downstream mediators. Early studies suggested that activation of PPARγ might antagonize the RAS by inhibiting expression of the Ang-II AT1R in vascular smooth muscle cells.9 PPARγ may also regulate expression of the renin and angiotensinogen (AGT) genes.10,11 TZD administration to Ang-II–treated Sprague–Dawley rats blunts the development of hypertension, endothelial dysfunction, and the induction of proinflammatory mediators.12 Similarly, TZD treatment of hypertensive transgenic mice overexpressing the renin and AGT genes improved endothelial function and lowered arterial pressure.13 An association between PPARγ and the RAS was also suggested by Tsai et al5 (and reviewed in Reference 14), who reported that mice carrying a mutant PPARγ allele equivalent to the mutation that causes hypertension in humans, exhibited increased blood pressure and elevated expression of AGT and AT1R in several adipose depots. That certain AT1R blockers exhibit partial PPARγ agonist activity suggests an unexpected, yet physiologically uncertain, link between PPARγ and the RAS.15 What remained unclear is whether this association between PPARγ and the RAS is clinically relevant?

In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Caron-Debarle et al16 explore this question in 4 members of 2 unrelated families with familial partial lipodystrophy associated with early-onset severe hypertension. Blood pressure control in these patients required aggressive treatment with multiple antihypertensive agents (including AT1R blockers) concurrent with treatment for hyperlipidemia, and in 3 of the 4 subjects, diabetes mellitus. They identified 2 previously unreported mutations in PPARγ. R165T occurs in a highly conserved residue in the DNA-binding domain, whereas L339X truncates the protein to lack a portion of the ligand-binding domain. All 4 patients were heterozygous for one of the mutations. In vitro studies of cultured fibroblasts and peripheral blood mononuclear cells derived from the patients, as well as human vascular smooth muscle cells transfected with the PPARγ mutants revealed that the mutant and wild-type alleles were equivalently expressed, but the mutants lacked transactivation capability. Unlike other mutations in PPARγ that cause hypertension, they do not act dominant negatively and most likely cause haploinsufficiency.3 TZD treatment improved glycemic control and eliminated the need for high-dose insulin therapy in 2 subjects, suggesting that the potential to activate the wild-type PPARγ allele was preserved. Although untested in the current study, it is possible that the activity of the wild-type PPARγ may have been impaired in these patients. Inflammation has been reported to impair PPARγ activity by cyclin-dependent kinase-5-mediated phosphorylation, an effect prevented by TZDs.17 Indeed, hypertension and diabetes mellitus are commonly associated with inflammation and fibroblasts isolated from these patients, exhibited increased nuclear factor kappa B activity, markers of inflammation, and increased ROS. AT1R signaling is well known to cause inflammation and oxidative stress, and interestingly, expression of AT1R, renin, and AGT were all markedly increased in patient fibroblasts and peripheral blood mononuclear cells, cells we do not immediately associate with the RAS. The increase in AT1R expression occurred concomitantly with increased Ang-II–induced extracellular signal-regulated kinase phosphorylation, and AT1R silencing prevented the induction of ROS and inflammation, suggesting that some of the pathological consequences of the mutations may be mediated by AT1R activation.

These data suggest a mechanism, whereby impaired PPARγ activity induces AT1R expression and signaling, which promotes oxidative stress and inflammation. That the silencing of AT1R in these cells also decreased expression of renin and AGT suggests their increase may be secondary to increased AT1R signaling. We could therefore hypothesize the existence (at least in the isolated cells from these patients) of a feed-forward mechanism, whereby elevated AT1R action augments further Ang-II production that may then amplify the pathological response (see Figure). It is interesting to note that the induction of renin expression by AT1R in fibroblasts and peripheral blood mononuclear cells is contrary to Ang-II–induced inhibition of renin expression in kidney. Unfortunately, information regarding the status of the systemic RAS in these patients before treatment was not available, whereas under therapy, 2 patients had normal plasma renin activity, plasma and urinary aldosterone, and potassium. Although the clinical relevance of the RAS in fibroblasts and peripheral blood mononuclear cells remains uncertain, AT1R signaling in vascular smooth muscle cells is of obvious importance in the regulation of vasomotor function. A feed-forward mechanism, as described above, could potentially induce endothelial dysfunction and smooth muscle contraction, and exacerbate the hypertension.

Figure.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

The peroxisome proliferator-activated receptor γ (PPARγ):renin–angiotensin system (RAS) relationship. Schematic showing that PPARγ mutations cause an increase in expression of the AT1 receptor (AT1R), which induces hypertension perhaps through reactive oxygen species (ROS) and inflammation. The increase in renin and angiotensinogen (AGT) elevates production of angiotensin-II (Ang-II), which in cells from the affected patients, causes a feed-forward mechanism, which may further increase AT1R signaling. Thiazolidinedione (TZD) treatment activates the wild-type PPARγ allele and blunts the effects of the mutation. A similar effect is attained by blocking AT1R expression by small interfering RNA, and presumably with AT1R blockers.

Regardless of the many strengths of this translational study, a number of important questions remain. First, did TZD treatment of the affected patients have an effect on arterial pressure; or in a more general sense, does PPARγ activation lower blood pressure in humans by antagonizing the RAS? We know that treatment of the patient fibroblasts with rosiglitazone, which presumably activated wild-type PPARγ, decreased expression of the RAS genes, and blunted the increase in ROS, nuclear factor kappa B, and interleukin-6 induced by the PPARγ mutations. Thus, at the cellular level, a normal phenotype could be rescued by activation of wild-type PPARγ by TZD. Even with the declining clinical use of TZDs, this may be important because new PPARγ activators, which do not act as full PPARγ agonists, are in development. At least one of these new compounds prevents impairment of PPARγ activity by posttranslational mechanisms induced by inflammation, and importantly, this compound may lack some of the detrimental side effects of TZDs.18 Its effect on the cardiovascular system has yet to be explored. Second, is the AT1R gene the primary PPARγ target gene or are there other PPARγ target genes in the relevant tissues, which become dysregulated in response to mutant PPARγ? We recently reported that PPARγ induces expression of a target gene in the aorta, which controls the activity of the Cullin-3 pathway, a regulator of RhoA/Rho kinase signaling and vasomotor function.19 We also recently identified a physiological connection between PPARγ and AT1R activity (but not AT1R expression) in mesenteric resistance vessels through Regulator of G-protein signaling 5, a novel PPARγ target gene that functions as a small GTPase-activating protein to regulate AT1R signaling.20 Third, are all the cardiovascular effects in these patients mediated by PPARγ and the RAS? This may be important to consider because there are other inherited lipodystrophies that are not caused by mutations in PPARγ, yet are associated with hypertension.21,22 A common feature of all these disorders is insulin resistance and a loss or redistribution of adipose tissue (eg, loss of subcutaneous adipose with accumulation of abdominal adipose).23 The mechanistic contributions of these features to hypertension in these patients remains unclear. Interestingly, as these patients often display evidence of inflammation (eg, increased plasma C-reactive peptide), a role for impaired PPARγ activity, and thus increased RAS activity, should be considered.

In closing, there are other familial partial lipodystrophy associated with early-onset severe hypertension subjects that carry different mutations in PPARγ and exhibit a much broader array of neurological and hematological symptoms, in addition to severe metabolic syndrome.24 It is therefore likely that PPARγ has far-reaching effects that may extend beyond RAS. Studies of human patients and patient cells like Caron-Debarle et al16 combined with studies using animal models will likely uncover other mechanistic links between PPARγ, the RAS, and other important pathways that may lead to effective therapies for the spectrum of disorders that encompass the metabolic syndrome.

Sources of Funding

This work was supported by National Institutes of Health grants HL048058, HL061446, HL062984, and HL084207 to C.D.S. The author also gratefully acknowledges the generous research support of the Roy J. Carver Trust.

Disclosures

None.

  • © 2013 American Heart Association, Inc.

References

  1. 1.↵
    1. Agostini M,
    2. Schoenmakers E,
    3. Mitchell C,
    4. et al
    . Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 2006;4:303–311.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Savage DB,
    2. Tan GD,
    3. Acerini CL,
    4. et al
    . Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes. 2003;52:910–917.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Barroso I,
    2. Gurnell M,
    3. Crowley VE,
    4. Agostini M,
    5. Schwabe JW,
    6. Soos MA,
    7. Maslen GL,
    8. Williams TD,
    9. Lewis H,
    10. Schafer AJ,
    11. Chatterjee VK,
    12. O’Rahilly S
    . Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880–883.
    OpenUrlPubMed
  4. 4.↵
    1. Dormandy JA,
    2. Charbonnel B,
    3. Eckland DJ,
    4. et al
    .; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tsai YS,
    2. Kim HJ,
    3. Takahashi N,
    4. Kim HS,
    5. Hagaman JR,
    6. Kim JK,
    7. Maeda N
    . Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J Clin Invest. 2004;114:240–249.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Beyer AM,
    2. Baumbach GL,
    3. Halabi CM,
    4. Modrick ML,
    5. Lynch CM,
    6. Gerhold TD,
    7. Ghoneim SM,
    8. de Lange WJ,
    9. Keen HL,
    10. Tsai YS,
    11. Maeda N,
    12. Sigmund CD,
    13. Faraci FM
    . Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension. 2008;51:867–871.
    OpenUrlCrossRef
  7. 7.↵
    1. Beyer AM,
    2. de Lange WJ,
    3. Halabi CM,
    4. Modrick ML,
    5. Keen HL,
    6. Faraci FM,
    7. Sigmund CD
    . Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103:654–661.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Halabi CM,
    2. Beyer AM,
    3. de Lange WJ,
    4. Keen HL,
    5. Baumbach GL,
    6. Faraci FM,
    7. Sigmund CD
    . Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7:215–226.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Takeda K,
    2. Ichiki T,
    3. Tokunou T,
    4. Funakoshi Y,
    5. Iino N,
    6. Hirano K,
    7. Kanaide H,
    8. Takeshita A
    . Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834–1839.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Vernochet C,
    2. Peres SB,
    3. Davis KE,
    4. McDonald ME,
    5. Qiang L,
    6. Wang H,
    7. Scherer PE,
    8. Farmer SR
    . C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol. 2009;29:4714–4728.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Desch M,
    2. Schreiber A,
    3. Schweda F,
    4. Madsen K,
    5. Friis UG,
    6. Weatherford ET,
    7. Sigmund CD,
    8. Sequeira Lopez ML,
    9. Gomez RA,
    10. Todorov VT
    . Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells. Hypertension. 2010;55:660–666.
    OpenUrlCrossRef
  12. 12.↵
    1. Diep QN,
    2. El Mabrouk M,
    3. Cohn JS,
    4. Endemann D,
    5. Amiri F,
    6. Virdis A,
    7. Neves MF,
    8. Schiffrin EL
    . Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation. 2002;105:2296–2302.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Ryan MJ,
    2. Didion SP,
    3. Mathur S,
    4. Faraci FM,
    5. Sigmund CD
    . PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43:661–666.
    OpenUrlCrossRef
  14. 14.↵
    1. Hegele RA,
    2. Leff T
    . Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest. 2004;114:163–165.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Benson SC,
    2. Pershadsingh HA,
    3. Ho CI,
    4. Chittiboyina A,
    5. Desai P,
    6. Pravenec M,
    7. Qi N,
    8. Wang J,
    9. Avery MA,
    10. Kurtz TW
    . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43:993–1002.
    OpenUrlCrossRef
  16. 16.↵
    1. Auclair M,
    2. Vigouroux C,
    3. Boccara F,
    4. Capel E,
    5. Vigarel C,
    6. Guerci B,
    7. Lascols O,
    8. Capeau J
    . Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin- angiotensin system. Arterioscler Thromb Vasc Biol. 2013;33:829–838.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Choi JH,
    2. Banks AS,
    3. Estall JL,
    4. Kajimura S,
    5. Boström P,
    6. Laznik D,
    7. Ruas JL,
    8. Chalmers MJ,
    9. Kamenecka TM,
    10. Blüher M,
    11. Griffin PR,
    12. Spiegelman BM
    . Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466:451–456.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Choi JH,
    2. Banks AS,
    3. Kamenecka TM,
    4. et al
    . Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477–481.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Pelham CJ,
    2. Ketsawatsomkron P,
    3. Groh S,
    4. Grobe JL,
    5. de Lange WJ,
    6. Ibeawuchi SR,
    7. Keen HL,
    8. Weatherford ET,
    9. Faraci FM,
    10. Sigmund CD
    . Cullin-3 regulates vascular smooth muscle function and arterial blood pressure via PPARγ and RhoA/Rho-kinase. Cell Metab. 2012;16:462–472.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ketsawatsomkron P,
    2. Lorca RA,
    3. Keen HL,
    4. Weatherford ET,
    5. Liu X,
    6. Pelham CJ,
    7. Grobe JL,
    8. Faraci FM,
    9. England SK,
    10. Sigmund CD
    . PPARγ regulates resistance vessel tone through a mechanism involving RGS5-mediated control of protein kinase C and BKCa channel activity. Circ Res. 2012;111:1446–1458.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Hegele RA,
    2. Anderson CM,
    3. Wang J,
    4. Jones DC,
    5. Cao H
    . Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res. 2000;10:652–658.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Kim CA,
    2. Delépine M,
    3. Boutet E,
    4. et al
    . Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93:1129–1134.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Hegele RA
    . Phenomics, lipodystrophy, and the metabolic syndrome. Trends Cardiovasc Med. 2004;14:133–137.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Campeau PM,
    2. Astapova O,
    3. Martins R,
    4. Bergeron J,
    5. Couture P,
    6. Hegele RA,
    7. Leff T,
    8. Gagné C
    . Clinical and molecular characterization of a severe form of partial lipodystrophy expanding the phenotype of PPARγ deficiency. J Lipid Res. 2012;53:1968–1978.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
April 2013, Volume 33, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Sources of Funding
    • Disclosures
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    A Clinical Link Between Peroxisome Proliferator-Activated Receptor γ and the Renin–Angiotensin System
    Curt D. Sigmund
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:676-678, originally published March 13, 2013
    https://doi.org/10.1161/ATVBAHA.112.301125

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    A Clinical Link Between Peroxisome Proliferator-Activated Receptor γ and the Renin–Angiotensin System
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    A Clinical Link Between Peroxisome Proliferator-Activated Receptor γ and the Renin–Angiotensin System
    Curt D. Sigmund
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2013;33:676-678, originally published March 13, 2013
    https://doi.org/10.1161/ATVBAHA.112.301125
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured